CNS biopharma is rapidly investing in digital technologies to revolutionize clinical identification and monitoring of complex neurological disorders through more objective, frequent, sensitive, and less invasive measures of movement, speech, and cognition.

Returning to Boston, the 2nd Digital Biomarkers & Clinical Measures in Neurology Summit is the only industry-specific meeting dedicated to developing translatable, scalable, and successful digital technologies and measures specifically to be incorporated into neurological clinical trials.

This is your must-attend meeting tackling the development of digital measures to revolutionize clinical assessments across neurological drug development.

Uniting Digital Health Biopharma with CNS Clinical Drug Developers to:

• Address the Standardization & Regulatory Acceptance of Digital Tools & Data Analysis as Endpoints in Complex Neurological Indications
• Discover Novel Innovations for Objective, Sensitive, & Non-Invasive Neurological Measures
• Ensure Confidence & Scalability with Emerging Digital Technologies

To know more visit: https://ter.li/nx0m2f